Salmonella flagellin, expressed as flagella in live attenuated vaccine strains, elicits distinct systemic (IgG) and secreted (IgA) antibody responses in mice following delivery via mucosal (nasal/oral) or parenteral (intraperitoneal (i.p.)) immunization routes. Reduced flagellinspecific antibodies were detected either systemically or locally following delivery of flagellated derivatives of aroA Salmonella enterica serovar Dublin SL1438 via the nasal route, the most effective mucosal site for activation of immune responses in mice. In contrast, flagellin represents the most potent Salmonella antigen for the generation of specific serum antibody (IgG) responses following i.p. inoculations. The distinct immunogenic properties of Salmonella flagellin could not be ascribed to deficient colonization, reduced invasive ability or loss of the flagellin expression by the flagellated vaccine strains. ß
Introduction
Salmonella £agellin represents one of the most relevant antigens for the generation of protective immunity in mice [1, 2] . Moreover, Salmonella £agellin has been shown to induce synthesis and secretion of proin£ammatory cytokines either in humans or mice [2^5] . Nonetheless, the £agellin-speci¢c systemic and secreted antibody responses induced following local delivery of attenuated Salmonella strains have been overlooked. Our previous observations indicated that Salmonella £agellin does not induce e¤cient systemic and secreted antibody responses following oral delivery of attenuated £agellated strains to mice [6] .
The antibody inducing properties of Salmonella £agel-lin, following local administration of attenuated strains to mucosal sites, is particularly relevant since bivalent Salmonella vaccine strains expressing hybrid £agella fused to heterologous epitopes derived from di¡erent organisms have been intensively studied as a potential vaccine approach able to elicit a broad array of immune responses, including the local production of secreted IgA (sIgA) against both bacterial and passenger epitopes [7, 8] . Particularly relevant is the fact that attempts to induce systemic and secreted antibody responses against heterologous epitopes fused to £agellin following oral administration of attenuated Salmonella strains have frequently failed [9^11] .
In this work we investigated the ability of £agellated Salmonella vaccine strain to elicit systemic and secreted £agellin-speci¢c antibody responses following inoculation of live Salmonella cells in the nasal cavities of mice, probably the most e¡ective mucosal administration route, either in mice or humans, for the generation of local (sIgA) and systemic (IgG) antibody responses both for soluble and particulate antigens.
Materials and methods

Bacterial strains and growth conditions
The attenuated Salmonella vaccine strains SL5928, SL5930 and ICB5 were derived from the Salmonella enter-ica serovar Dublin SL1438 aroA strain [6, 7] . Strain SL5928 (a non-£agellated strain) has a Tn10 insertion at the £agellin-encoding gene, £iC, while strain SL5930 harbors pLS408, a pBR322 derivative with a cloned £iC gene [7] . The ICB5 strain was obtained after the integration of the £iC gene into the chromosome of strain SL7379, a hisD derivative of SL5928, as previously described [6] . Both SL5930 and ICB5 strains express similar amounts of £agellin as evaluated in immunoblots and produced morphologically and functionally normal £agella [6] . The Salmonella strains were grown aerobically at 37³C in Luria broth (LB) and, when required, supplemented with ampicillin (100 Wg ml 31 ).
Immunization experiments
Female C57BL/6 mice, 8^12 weeks old, were from the Animal Breeding Center of the Biomedical Sciences Institute at the Sa ¬o Paulo University. Immunizations were carried out with exponential-phase cells (optical density (OD) of 0.8 at 600 nm). Bacteria were washed once with phosphate-bu¡ered saline (PBS) and suspended in sterile water, or in 3% sodium bicarbonate for the peroral (p.o.) inoculations, to obtain di¡erent concentrations ranging from 5U10 8 10 CFU. The same immunization schedule (days 0, 21 and 35) was followed for both i.p. or p.o. experiments. Blood was drawn from the retro-orbital plexus 1 week after the last dose. Mice were killed by means of cervical dislocation and lung washes collected in 0.5 ml sterile PBS with the aid of a thin plastic cannula inserted in the trachea. Samples were transferred to microcentrifuge tubes and the supernatants collected after centrifugation at 5000Ug for 5 min at 4³C. Blood-containing lung wash samples were discarded. Sera and lung wash samples were both stored at 320³C until testing.
Measurement of antibody responses by enzyme-linked immunosorbent assay (ELISA)
Lipopolysaccharide (LPS)-and £agellin-speci¢c serum IgG and lung wash IgA were measured following standard procedures [6] . Maxisorp plates (Nunc, Rosckilde, Denmark) were coated overnight at 4³C with 1 Wg per well of group D Salmonella LPS (Sigma) or 0.1 Wg per well of puri¢ed S. enterica serovar Dublin £agellin, prepared as previously described [6, 11] . Plates were washed three times in PBS^0.05% Tween 20 (PBS-T) and blocked with 1% gelatin in PBS-T for 2 h at 37³C. Serial 2-fold dilutions of either sera or lung washes (100 Wl per well) in PBS-T were incubated for 2 h at 37³C, followed by three washes with PBS-T and an additional incubation hour with PBS-T-diluted (1:1000), peroxidase-conjugated goat antibodies against mouse heavy chain-speci¢c IgA or IgG isotypes (Sigma). Plates were ¢nally washed with PBS-T and developed for bound peroxidase with O-phenylene diamine dihydrochloride and H 2 O 2 as substrate. Endpoint titers were expressed as the reciprocal values of the last dilution with an OD of 0.1 at 492 nm above maximal absorbance values of samples collected from non-immunized animals (for anti-LPS responses) or from animals immunized with SL5928 (for anti-£agellin responses).
Immunoblot analyses
Detection of serum anti-£agellin antibodies in immunoblots was carried out with total protein extracts of SL5930 strains. The exponentially growing Salmonella cells were harvested by centrifugation, suspended in electrophoresis sample bu¡er and boiled for 5 min. Proteins were sorted in 10% polyacrylamide gels and transferred to nitrocellulose ¢lters by standard procedures [12] . After blocking with 5% skim milk in PBS-T for 1 h, the nitrocellulose ¢lters were incubated for 2 h at room temperature with sera from mice immunized with the Salmonella vaccine strains via di¡erent routes. Serum samples were diluted with PBS-T to concentrations ranging from 1:50 to 1:1000. Rabbit anti-£agellar antigen d serum (diluted 1:1000) (Difco, Detroit, MI, USA) was used as a positive control for £agellin detection. Development of reactive antibodies was carried out with peroxidase-conjugated goat anti-mouse IgG or goat anti-rabbit IgG (Sigma), diluted in PBS-T containing 5% skin milk, and the ECL quimioluminescence kit (Amersham Corp., Arlington Heights, USA).
Detection of viable Salmonella cells in mouse tissues
Three groups of 15 female C57BL/6 mice were i.n. inoculated with a single 10 7 CFU dose of the Salmonella vaccine strains (SL5928, SL5930 or ICB5). Mice were killed on various times after inoculation ranging from 1 to 20 days. Lungs and spleens were aseptically removed and homogenized individually in 1 ml of sterile PBS. Tissue homogenates were serially diluted in PBS and plated on LB agar plates for viable cell counting.
Evaluation of in vivo plasmid stability
The stability of pLS408 in strain SL5930 was determined by the number of ampicillin resistant colonies recovered from lungs, spleens, and Peyer's patches of mice inoculated with a single dose of 10 7 CFU (i. (Fig. 1) . On the other hand, mice i.p. immunized with strains SL5930 or ICB5 developed strong systemic (IgG) antibody responses against £agellin. Under the immunization conditions used in this work, £agellin represented by far the most potent Salmonella antigen as regards the generation of serum antibody responses detected in immunoblots (Fig. 1) . Analysis in ELISA of the systemic and secreted antibody responses elicited by the Salmonella vaccine strains showed that the i.n. immunization resulted in serum LPS-speci¢c IgG responses similar to those attained following parenteral administration, which con¢rms the performance of the i.n. route as an e¤cient mucosal immunization approach ( Fig. 2A) . On the other hand, the serum £agellin-speci¢c IgG responses developed in mice following p.o. or i.n. inoculation of Salmonella SL5930 or ICB5 strains were marginal (Fig. 2B) . Stabilization of £agellin expression in ICB5 did not change signi¢cantly the serum antibody responses elicited in mice immunized via the mucosal routes (Fig. 2) . Immunization trials carried out with larger doses (10 8 or 10 9 CFU) delivered via the i.n. route resulted in death of more than 50% of the inoculated animals. Moreover, the serum £agellin-speci¢c IgG levels among the survivors were not higher than those found in mice immunized with 10 7 CFU (data not shown). Low anti-£agellin sIgA responses were detected in lung washes of i.n. immunized mice which have received three doses of 10 7 CFU of the £agellated Salmonella SL5930 or ICB5 strains, whereas higher LPS-speci¢c antibody levels were observed (Fig. 3) . I.n. administration of larger inoc- ula (10 8 or 10 9 CFU) did not improve the local £agellin-speci¢c IgA responses, as evaluated in survivors submitted to these immunization regimens (data not shown).
Colonization/invasion abilities and £agellin expression of the Salmonella vaccine strains
The reduced immunogenicity of £agellin following mucosal delivery of attenuated Salmonella strains might re£ect de¢cient colonization or reduced ability to invade deeper tissues. Colonization, measured by survival at the lung environment, and spleen invasion were determined for periods up to 20 days following inoculation of 10 7 CFU of the Salmonella SL5928, SL5930 and ICB5 strains. As observed in Fig. 4 , the tested Salmonella strains showed similar behaviors as regards to colonization and invasion abilities, evaluated by the number of viable cells in lungs or in spleens of inoculated mice, respectively.
Reduced antigen load due to loss of £agellin expression by the SL5930 or ICB5 strains could have a negative e¡ect on the activation of £agellin-speci¢c secreted and systemic antibody responses. Therefore, stability of £agellin expression was monitored following p.o. or i.n. inoculation of mice either by the number of ampicillin resistant colonies, for the SL5930 strain, or by positive results in colony blots developed with £agellin-speci¢c antibodies, for the ICB5 strain. As shown in Table 1 , stability of the £agellin-encoded plasmid measured in colonies recovered from Peyer's patches or spleens of mice p.o. inoculated with SL5930 strain was reduced, as regards the number of ampicillin resistant colonies recovered from lungs and spleens of i.n. inoculated mice. On the other hand, all colonies recovered from mice inoculated with the ICB5 strain via the mucosal routes were positive for £agellin expression. 
Discussion
Recombinant attenuated Salmonella strains expressing hybrid £agellin have been designed as an elegant and simple approach to deliver heterologous epitopes derived from diverse pathogens to the mammalian immune system inductive sites [8, 9] . One of the main appeals of such vaccine approach relied on the possibility to induce local and systemic antibody responses against host and heterologous antigens after mucosal delivery of the attenuated strains. However, our ¢ndings shows that Salmonella £agellin does not e¤ciently activate systemic or secreted antibody responses after p.o. or i.n. administration to mice. The low immunogenicity of £agellin following delivery at the nasal inoculation route was surprising since it has been shown to be the most sensitive mucosal site for generation of antibody responses both for humans and rodents [13^15]. These results suggest that £agellin does not represent an e¤cient protein carrier for activation of secreted and systemic antibody responses to B-cell epitopes fused to it when delivered at mucosal sites as a cellular component of live Salmonella strains.
The reduced immunogenicity of £agellin delivered at mucosal sites contrasted with the strong antibody responses attained after parenteral delivery of £agellated Salmonella cells. Some explanations for the distinct immune responses elicited by Salmonella £agellin delivered at di¡erent immunization sites would be a de¢cient mucosal colonization or reduced invasive ability of £agellated Salmonella cells. Nonetheless our present data and previous observations [6] have demonstrated that the £agel-lated SL5930 and ICB5 strains show no signi¢cant impairment, in relation to the non-£agellate strain, in their colonization or invasive properties. The lack of £agellin-speci¢c antibody responses in mice mucosally inoculated with ICB5 strain demonstrated also that loss of £agellin-encoding gene does not contribute to the low antibody yields following delivery at mucosal sites. Moreover, low immunogenicity of £agellin following delivery at mucosal sites does not represent a case of tolerance since mice orally immunized with live £agellated Salmonella cells can induce strong antibody responses against parenterally administered £agellin (unpublished observations).
The low immunogenicity of Salmonella £agellin delivered at mucosal sites may re£ect the action of gene regulation mechanism operating during in vivo replication. The £agellin-coding gene present in the Salmonella vaccine strains remains under the control of the native promoter, which, although strong, may be negatively regulated during replication inside mammalian cells, reducing the amount of antigen available for activation B-cell dependent responses. On the other hand, some authors suggested that local and systemic antibody responses induced against a heterologous antigen expressed by Salmonella strains do not require in vivo expression or even viability of the bacterial cells [16] . Expression of Salmonella £agel-lin under the control of constitutive or in vivo induced promoters is an attempt worth to pursue in order to improve the immunogenicity of mucosal delivered £agellated strains. Moreover, elucidation of the gene regulation mechanism a¡ecting £agellin expression during in vivo growth should also help to design more rational vaccine approaches based on attenuated Salmonella strains.
The lack of antibody responses to £agellin in mice immunized at mucosal sites with live Salmonella cells could also mean that the elicited immune responses do not activate B-cells and, therefore, do not lead to antibody production. Previous evidences indicated that £agellin represents the most relevant antigen for the development of a protective cellular immune response in mice orally immunized with attenuated Salmonella strains [1, 2] . Moreover, recent reports have shown that Salmonella £agellin is a strong inducer of in£ammatory cytokines in vitro cultured human mononuclear cells [3, 4] . Taken together, these results suggest that Salmonella £agellin can induce cellular immune responses in mice, but not antibody production, when attenuated strains are delivered at mucosal sites. Further experiments are required to demonstrate that delivery of £agellated Salmonella vaccine strains at murine mucosal sites can activate cell-mediated immune responses against heterologous epitopes fused to £agellin.
